ADORA2A and neoplasm: Personalized approaches, based on the tumor adenosinergic signature, receptor expression profiling, and functional imaging (e.g., PET tracers for CD73 or A2AR), may further refine the therapeutic index of adenosine-targeted therapies in the clinical setting [57].